0001104659-23-115048.txt : 20231107 0001104659-23-115048.hdr.sgml : 20231107 20231107090704 ACCESSION NUMBER: 0001104659-23-115048 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231107 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231107 DATE AS OF CHANGE: 20231107 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Milestone Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001408443 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38899 FILM NUMBER: 231381917 BUSINESS ADDRESS: STREET 1: 1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420 CITY: MONTREAL STATE: A8 ZIP: H4M 2X6 BUSINESS PHONE: (514) 336-0444 MAIL ADDRESS: STREET 1: 1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420 CITY: MONTREAL STATE: A8 ZIP: H4M 2X6 8-K 1 tm2330059d1_8k.htm FORM 8-K
false 0001408443 A8 00-0000000 QC 0001408443 2023-11-07 2023-11-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):

November 7, 2023

 

MILESTONE PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

 

Québec   001-38899   Not applicable
(state or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)

 

1111 Dr. Frederik-Philips Boulevard,    
Suite 420    
Montréal, Québec CA   H4M 2X6
(Address of principal executive offices)   (Zip Code)

 

Registrant's telephone number, including area code: (514) 336-0444

 

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which
registered
Common Shares   MIST   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

 

 

 

 

 

 

Item 7.01. Regulation FD Disclosure.

 

On November 7, 2023, Milestone Pharmaceuticals Inc. (“Milestone” or the “Company”) issued a press release announcing the Company will host a virtual investor and analyst webcast on Monday, November 13, 2023 at 8:00 a.m. ET, which will focus on results from the ReVeRA Phase 2 study of investigational new drug etripamil in patients with atrial fibrillation with rapid ventricular rate. A copy of the press release is attached hereto as Exhibit 99.1. To access a live or recorded webcast of the event and accompanying slides, please visit the News & Events section of Milestone’s investor relations website at investors.milestonepharma.com.

 

The Company intends to use its website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. Such disclosures will be included on its website in the “Investors & Media” section. Accordingly, investors should monitor such portions of its website, in addition to following press releases, filings with the U.S. Securities and Exchange Commission (the “SEC”) and public conference calls and webcasts.

 

The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, or the Securities Act. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing with the SEC, made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

Item 9.01. Financial Statements and Exhibits

 

(d) Exhibits.

 

Exhibit No. Description
99.1 Press release, dated November 7, 2023
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  MILESTONE PHARMACEUTICALS INC.
   
Date: November 7, 2023 By: /s/ Amit Hasija
    Amit Hasija
    Chief Financial Officer Principal Financial Officer

 

 

 

 EX-99.1 2 tm2330059d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

Milestone Pharmaceuticals to Host Investor and Analyst Webcast to Review Data from ReVeRA Phase 2 Study of Etripamil in AFib-RVR

 

-      Cardiac Electrophysiology Key Opinion Leaders joining the webcast include A. John Camm, MD, and Sean Pokorney, MD

 

-      Conference call and webcast on Monday, November 13, 2023 at 8:00 a.m. ET

 

MONTREAL and CHARLOTTE, N.C., Nov. 7, 2023 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that the Company will host a virtual investor and analyst webcast on Monday, November 13, 2023 at 8:00 a.m. ET. The webcast will focus on results from the ReVeRA Phase 2 study of investigational new drug etripamil in patients with atrial fibrillation with rapid ventricular rate (AFib-RVR), which is being presented as a Featured Science presentation at the American Heart Association (AHA) Scientific Sessions 2023.

 

Joining Milestone’s management team will be:

 

·A. John Camm, M.D., Author on the ReVeRA AHA Featured Science presentation and British Heart Foundation Emeritus Professor of Clinical Cardiology, The Cardiology Clinical Academic Group, Molecular and Clinical Sciences Research Institute, St. George's University of London, London, UK

·Sean Pokorney, MD, MBA, Director of the Arrhythmia Core Laboratory, Duke Clinical Research Institute, Assistant Professor of Medicine, Duke University School of Medicine, Durham, NC

 

To access the live call by phone, dial (877) 870-4263 (domestic) or (412) 317-0790 (international) and ask to be connected to the Milestone Pharmaceuticals call. To access a live or recorded webcast of the event and accompanying slides, please visit the News & Events section of Milestone's investor relations website at investors.milestonepharma.com.

 

About Atrial Fibrillation with Rapid Ventricular Rate

 

An estimated five million Americans suffer from atrial fibrillation (AFib), a common arrhythmia marked by an irregular, disruptive and often rapid heartbeat. Incidence of atrial fibrillation (AFib) in the United States is expected to grow to approximately 10 million by 2025 and up to about 12 million by 2030. A subset of AFib patients experience episodes of abnormally high heart rate most often accompanied by palpitations, shortness of breath, dizziness, and weakness. While these episodes, known as AFib-RVR, may be treated by oral calcium channel blockers and/or beta blockers, patients frequently seek acute care in the emergency department to address symptoms. In 2016, nearly 800,000 patients were admitted to the emergency department due to AFib symptoms where treatment includes medically supervised intravenous administration of calcium channel blockers or beta blockers, or electrical cardioversion. With little available data for AFib-RVR, Milestone's initial market research indicates that 30-40% of patients with AFib experience one or more symptomatic episodes of RVR per year that require treatment, suggesting a target addressable market of approximately three to four million patients in 2030 for etripamil in patients with AFib.

 

 

 

 

About Etripamil

 

Etripamil is Milestone's lead investigational product. It is a novel calcium channel blocker nasal spray under clinical development for elevated and often highly symptomatic heart-rate attacks associated with paroxysmal supraventricular tachycardia (PSVT) and atrial fibrillation with a rapid ventricular rate (AFib-RVR). It is designed to be a rapid-response therapy that is self-administered by the patient, without the need for direct medical oversight. If approved, etripamil is intended to provide health care providers with a new treatment option to enable on demand care and patient self-management. If approved, the portable treatment, studied as self-administered, may provide patients with active management and a greater sense of control over their condition. Etripamil, proposed brand name CARDAMYST™, is well studied with a robust clinical trial program that includes a completed Phase 3 clinical-stage program for the treatment of PSVT and Phase 2 proof-of-concept trial for the treatment of patients with AFib-RVR.

 

About Milestone Pharmaceuticals

 

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular medicines to benefit people living with certain heart conditions. Milestone recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for etripamil for treatment of an abnormal heart rhythm, paroxysmal supraventricular tachycardia or PSVT. Find out more at www.milestonepharma.com.

 

Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believe," "continue," "could," "demonstrate," "designed," "develop," "estimate," "expect," "may," "pending," "plan," "potential," "progress," "will" and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Milestone's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements regarding the anticipated growth of incidence of AFib and AFib-RVR by 2030; and the ability of etripamil to act as a rapid-response therapy that is self-administered by the patient, without the need for direct medical oversight and to provide health care providers with a new treatment option to enable on demand care and patient self-management. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, the risks inherent in biopharmaceutical product development and clinical trials, including the lengthy and uncertain regulatory approval process; uncertainties related to the timing of initiation, enrollment, completion, evaluation and results of our clinical trials; risks and uncertainty related to the complexity inherent in cleaning, verifying and analyzing trial data; and whether the clinical trials will validate the safety and efficacy of etripamil for PSVT or other indications, among others, general economic, political, and market conditions, including deteriorating market conditions due to investor concerns regarding inflation and Russian hostilities in Ukraine and overall fluctuations in the financial markets in the United States and abroad, risks related to pandemics and public health emergencies, and risks related the sufficiency of Milestone's capital resources and its ability to raise additional capital in the current economic climate. These and other risks are set forth in Milestone's filings with the U.S. Securities and Exchange Commission, including in its annual report on Form 10-K for the year ended December 31, 2022, under the caption "Risk Factors," as such discussion may be updated from time to time by subsequent filings, we may make with the U.S. Securities and Exchange Commission. Except as required by law, Milestone assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

 

Contact

 

Kim Fox, Vice President, Communications

kfox@milestonepharma.com

704-803-9295

 

 

 

 EX-101.SCH 3 mist-20231107.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 mist-20231107_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 mist-20231107_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2330059d1_ex99-1img001.jpg GRAPHIC begin 644 tm2330059d1_ex99-1img001.jpg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ⅅ!D=0RL#P0>]17EW!8VLES0B;> <$@'TS2@ MU\Z7WBB\U_QU!?+-+%$UW$D4:N0 @<8R/7N?K7<_%G4M=LY+"#3GGBM'0L[P M@Y+@]"1[8KK>$DI1A?5E9WVJZR?@S)>WKRP:AM5=_P!UBOFA0?J5 MJ3X/WUW?:/J1N[F6\.6UK MIL'G3+>)(PW 84(XSS[D57\$^!KSPZ_VBXU%LNOS6\7W"??/]*?\5-4OM)\, MVMQI]S);S&]1"Z=2-CG'Y@57\!^*]>UU0MY8"2V48:]7Y!GW!X)]<=/2NQ>T M^KZ6Y;E?9+\OC.ST[Q%>:?<6IC"2 &9!G=\HY-:>KNNM^'7.GLLP8 (3M&,J/F/KVJO9:M>?8+\QR^4(UC*)&H" MKEP.!2]DI14H]#CGBZ:KQH)>\_N+%A>1:,0Z7+3.1DQQ_<)QW/\ A6]JEX+I MOLK.\(PIW+R#D \_G6%:6\>IPF2XMU@C0'==(0H'U!X/X5LZG"(2UQ;Q?:G5 M5W(&&%&T8) Y-*5N96W(O43G]8:M;2W]7)M!LIK6YED8JT17"NIX/-3WFOVD M8*Q_OCR"!T_.LK1=3N;E[K?)@+&"JJ,!?F'2KDEA:W,;/*BP@I[NXFM+!' MM8O/ 4<^@QUJAHFH7%[J$@EDROEDA0.!R*A7Y7V-)2@JD4]SH!2T@I:R.PBN M/^/:3_OAM;Q7?CBV@GC6 M2*2.971AD,#&V17I8&7+&*#J6E-H]TY-U9(/+)_BBS@?\ ?.0/ MRK*^+OBE6">'K5P\@.)H0SH?1 MA'P?SKFY?W$HK^870W_$OQ7M-)OI;+3K7[9+$2KR%L(&'4>^,5F:5\9-UXD> MJZ<(8B0&>)B2ON1BO/?#%_<6&L&^BTG^U)$4_NV0L%)(PQP#S_C6OXIU+5?% M A9_"[VLT;9\Z*!]S#'0_+]#71]5IQ?(XZ=[CL>R>)/%MEX>T%-5?]\LVT0* MA_UA89&/;'->=+\9[\R[CI$/DD_\]#G\\4Z?PUK&O?"G2E$,IO;&60K!("&: M++ ]P,8^E8?A[QS'I5E'H^LZ+;W5BA*/F,"0<\Y!X)Z^E94J,.1Z>)/'C1>!;34ETUU_M,/"(Y&QM!5AN]\]17EW@_Q2WA/5)[Y;9;AI(3#M9M MN,L#G]*]KFET3Q)X(FN+6&"XLXK9_)5D_P!4RH0!@]"*\O\ A-I]GJ7B2[BO MK6*XC%FS!94# '>G/-%!PC2G>/J-6L>G>&?&T&L^&;C7+V);*&"5D0 M/?!_"K_PU\+:1_PB5KJ$]E!Q/:MCQOXQ;PC;6 MS6,$]S@XKSOQ%8 MP:+\3VM[)?+BBNX'C5>BYV-@?B:J-.C-RIJ.JZAHSVOQ-XIL/"^G"ZO22S'$ M<2_><]\?2O-Y/C->&8M'H\7D X^:0Y_/%9?Q>O9;CQ>ELV1%:VZA1[MDD_R_ M*I[3Q7J=IHZZ:G@J-K<)L93"YW]LGY>3[T4L/&--2<;MC2T/2_"'C2S\66KF M%&AN8L>;"QY'N/4=:Z>O ?AU9ZM9>.[*1;&[@MY-Z2[HF"[-I(!)'J!7OHZU MR8FG&G.T=B9*PM%%%(-"MK234(+$+=K())NA.UQM'( MYY_2I?#G@G1] CCDAA\ZZ0Y70YG4/#.LZAXNO[FSC M:"-I05N&;8/NCD8Y/X5UD]K;Z-HK37T:W;C:LLGEJ&?YACZX/K7-7GC#4M+\ M77MK@7%JLH582.0-H^Z1SWKK+J.3Q#H!3RWM'E(.V9>5PP/3\*;8)*] MN8XJZM+K4&:6VN?MD8^[&3M=1Z!.GY5T%[$\%R;B5Q @1/G=MO11G'<_A6QI MV@66GHI1-\J_\M&Y/_UJL7^EVFH1A+J(2 =">H^AHE54FD]D<$,*L/*$R9"H&1D5 M.;2#4M/@^U()"4!R>H)')JEIFCQZ9JLC1W 8-&0(S]X#(Y^E8I1L[[G;)U>> M"BER_B;HI:04M9'80W'_ ![2?[A_E7@'PN_Y*!9]>%E)]OD:OH0\U6AT^TMY M"\%O%&YZLB &MZ5;V<91MN-.QROQ%\)OXET-6LXPVHVS;H1D#>#U4D_G]15_ MP5X:7PSX,G(P?7C/M707OQ?U>_F@ATC2XX7W E23,\G^R M ,9Z=S7L=S96M["T-U!'-&W5)%# _@:KV6AZ5IK%K'3[:V8]3%$%)_*M7B: MG"\A\R.=\9^*+S0/"L.H6MKB[E>,%)4++'D;F#8Z< CKU->8^+?'6G>*- M'2$Z&D&H;U;[3O!V>N" "<],'CO7OCPI(A1U#*W!4C(-9L7AG0H+@7$.D64< MP.0ZP*"#]<5G1JTZ>KCKZB31P_PUT:_M_ ^JK7/&ZD',>;&?4OB?X&OS);0I?6=V'MEC!56&WIDGKRWX@5S7 MAKQ[JW@Z!]+GLA- C$K#/F-XV)Y[=/P^E>^I#'$@2-0J@8 48%4[[1-+U,J; MZPMKDK]TRQ!B/IFB.(C9PE&\0NCPH/K7Q/\ $T)>+;"GRG8,)!'G)Y/?^?T% M=9\8X([71=$MXE"112,B+Z * !^E>HVUG;6<(AMH(X8EZ)&H4#\J6>U@N5"S MPI*H.0'4'%'UKWXM*RCT'S:G,_#8_P#% Z7_ +LG_HQJ\M\<_P#)69?>XMO_ M $".O>HH8H(ECB0(B]%48 J)["SEF\Y[:)I>/G9 3QTYJ*=?DJ2G;>_XB3/, M/BYX7N[R6WUNS@,RQQ^3<*@RP&+-5UVQU&ZU:U;RX3YD4L<6U2,'*#GYB,?K76:?XATW4[UK.UG+7"1 MB5D*D87C]>16BL2(@1%"J!C '&*;';0Q/N2-%;!&0 .O7^0K" M$\4Z;AM1N2EGC_CVD;>W MX?W:]!95888 CW%+6WMG[/V=AWTL4H]+LH[R2[6UB$\AW/)M&2<8J[@445B( M**** #%5[JSM[N+9/"DB^C#-6**:=MA22:LS)U:TO9+ 0Z=*(648QT)'H#VK M$\-6=];:W-]LC<,83\QY!Y'>NQI-H!S@9K2-1J+CW.6>%4JL:MWITZ *6BBL MCK"BBB@ HHHH XJUCU2XUZ6:W>;RH[YUD9I/DV#^''K4=[J.H)I^LI'$[1K< MR#S_ #,>6,CC'^>M=M'#%%N\N)$WL6;:H&2>I/O3#9VICDC-M"4E):12@PY/ M:\%+E:4][_B)2,< M>G%)'96L6SR[:%-BE5VQ@;0>H'L:ES@T].Y<<-5C.+Y]%;3O96_KY'+:5XA- MUXDGB:0&"X)$2_W2O^/)HTL#4)_MMSJ6\I<[O7..M-U(]%8F&%JZ>TDG9M]3E(#/ M<>*[E7EF\J.X&,3;0. <;>])=ZA)':Z_%]I99EN (EW<@$CI77?8+,3&86D' MFD[B_EC<3ZYIKZ982R-))8VSNQ!9FB4DD="3BFJJO>W83P4^5I2U;??K7Q#)$[%HHXC&">%RO)_K72M!"\B2-$ MADCSL8J"5SUP>U-:TMF,I:WB/G "3*#YQTP?7\:GVBT37]7-7A7>3B[7?Z6_ M/4Y_0XX8@EU_:LMP[P%Y$:3([$MCMCI5?0_$7V_7+F)Y/W<^3 G==O&/Q S7 M21:;8P9\FRMH\J4.R)1\IZC@=*2+2]/@D62&PM8Y$^ZR0J"/H0*'.+O=;BCA MJD>3EDDEOOJ9FBW#2PWT;3YE%W*%RXGD>?RPY_>;T89 M^\/3-=+'96L4C21VT*.Q)++& 23UYHALK2W??#:PQOMV[DC ./3CM0ZBU5MQ :QPTHN#O\/KYDP[4M%%8G<%%%% !1110!_]D! end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Nov. 07, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 07, 2023
Entity File Number 001-38899
Entity Registrant Name MILESTONE PHARMACEUTICALS INC.
Entity Central Index Key 0001408443
Entity Tax Identification Number 00-0000000
Entity Incorporation, State or Country Code A8
Entity Address, Address Line One 1111 Dr. Frederik-Philips Boulevard
Entity Address, Address Line Two Suite 420
Entity Address, City or Town Montréal
Entity Address, State or Province QC
Entity Address, Country CA
Entity Address, Postal Zip Code H4M 2X6
City Area Code 514
Local Phone Number 336-0444
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares
Trading Symbol MIST
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period true
XML 8 tm2330059d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001408443 2023-11-07 2023-11-07 iso4217:USD shares iso4217:USD shares false 0001408443 A8 00-0000000 QC 8-K 2023-11-07 MILESTONE PHARMACEUTICALS INC. 001-38899 1111 Dr. Frederik-Philips Boulevard Suite 420 Montréal CA H4M 2X6 514 336-0444 false false false false Common Shares MIST NASDAQ true true EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

JQ"(6 M,P$ "(" / " ;$0 !X;"]W;W)K8F]O:RYX;6Q02P$" M% ,4 " #A2&=7)!Z;HJT #X 0 &@ @ $1$@ >&PO M7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " #A2&=799!YDAD! M #/ P $P @ 'V$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+ 4!08 "0 ) #X" ! % ! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 25 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://milestonepharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports mist-20231107.xsd mist-20231107_lab.xml mist-20231107_pre.xml tm2330059d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2330059d1_8k.htm": { "nsprefix": "mist", "nsuri": "http://milestonepharma.com/20231107", "dts": { "schema": { "local": [ "mist-20231107.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "mist-20231107_lab.xml" ] }, "presentationLink": { "local": [ "mist-20231107_pre.xml" ] }, "inline": { "local": [ "tm2330059d1_8k.htm" ] } }, "keyStandard": 25, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 5, "http://xbrl.sec.gov/dei/2023": 5 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 25 }, "report": { "R1": { "role": "http://milestonepharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-11-07", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2330059d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-11-07", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2330059d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://milestonepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001104659-23-115048-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-115048-xbrl.zip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